

October 29, 2026

To The Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Code: 540222	To The Listing Department National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 Code: LAURUSLABS
--	--

Sub: **Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Acquisition**

Dear Sir / Madam,

Pursuant to Regulation 30 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we would like to inform that the Board of Directors of the Company at its meeting held today, i.e., on October 29, 2026, *inter alia*, has approved for acquisition of 52% share capital of SI & C Resins Private Limited (“SI&C”) at a pre-money valuation of Rs. 30 Crore. The Company proposes to invest a total of Rs. 32.50 Crores by way of primary acquisition of 10,833 equity shares, equivalent to 52% of post-issue equity capital on Closing (the “Proposed Transaction”).

SI&C specializes in the manufacturing and supply of high-quality polymer and silica-based products for the chemical, pharmaceutical, and biotechnology industries.

Following such acquisition, the Company shall hold 52% of the equity share capital of SI&C, and SI&C will be a subsidiary company of the Company.

The Company may also invest up to Rs. 30 Crores in the securities to be issued by SI&C as and when funds are required by SI&C.

The disclosure pursuant to Regulation 30 of the SEBI Listing Regulations read with Part A of Schedule III of the SEBI Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is annexed herewith in Annexure-A.

The Board Meeting commenced at 02.00 p.m. (IST) and concluded at 02.47 p.m. (IST).

Please take the above information on record.

Thanking you.

Yours faithfully,

For Laurus Labs Limited

VANTARAM
VENKATA RAVI
KUMAR

Digitally signed by
VANTARAM VENKATA RAVI
KUMAR
Date: 2026.10.29 15:03:55
+05'30'

V V Ravi Kumar

Executive Director and CFO

DIN: 01424180

Encl: A/a

Registered Office

Laurus Labs Limited

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District – 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, **F** +91 891 682 1103
E info@lauruslabs.com, **W** lauruslabs.com

Corporate Office

Plot No. 103, Road No 1, Jubilee Hills,
Hyderabad, Telangana – 500 033, India.

T +91 40 6659 4333
F +91 40 6659 4320

CIN : L24239AP2005PLC047518

Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

a	Name of the target entity, details in brief such as size, turnover etc.	<u>Name of the target entity</u> SI & C Resins Private Limited (“SI&C”) situated in Hyderabad, India. <u>Details in brief</u> SI&C specializes in the manufacturing and supply of high-quality polymer and silica-based products for the chemical, pharmaceutical, and biotechnology industries. Wide range of products for various applications are as hereunder: ○ Peptide and Peptidomimetic Synthesis; ○ Absorption and separation of the heavy metals; ○ Oxidation and reduction of the functional groups; ○ Counter – Ion exchange of small molecules and APIs <u>Turnover</u> Not applicable. SI&C is incorporated recently in July, 2026. SI&C will take over the business of a partnership firm, namely, M/s SI & C Resins (the “Firm”), wherein all the founder directors and shareholders of SI&C, are partners in the Firm. The Firm was registered in the year 2022 and has turnover for the financial year 2024-25 was Rs. 3.55 Crore and for 2025-26 was Rs. 4.05 Crore.
b	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	The acquisition would not fall within related party transaction. The promoter/ promoter group/ group companies of the Company have no interest in SI&C.
c	Industry to which the entity being acquired belongs	SI&C specializes in the manufacturing and supply of high-quality polymer and silica-based products for the chemical, pharmaceutical, and biotechnology industries.
d	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	As part of the overall Peptide strategy, the Company proposes to acquire a majority equity in SI&C and this will make Laurus offerings in Peptide manufacturing fully integrated. The proposed investment in SI&C will bring synergy to the business of the Company, while SI&C continue to develop new markets for its products. Indigenous resins, chromatography gels development, and large-scale manufacturing will help to capture fully integrated peptide manufacturing opportunities. Further, SI&C will set

Registered Office

Laurus Labs Limited

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, **F** +91 891 682 1103

E info@lauruslabs.com, **W** lauruslabs.com

Corporate Office

Plot No. 103, Road No 1, Jubilee Hills,
Hyderabad, Telangana - 500 033, India.

T +91 40 6659 4333

F +91 40 6659 4320

CIN : L24239AP2005PLC047518

		up a large-scale manufacturing plant by SI&C for peptide resins as solid phase peptide synthesis (SPPS) supports and chromatography gels. The acquisition will help us to build on the existing customer base and product pipeline to scale domestic resin manufacturing solutions for pharma and peptide manufacturing.
e	Brief details of any governmental or regulatory approvals required for the acquisition	The acquisition will be in accordance with the applicable provisions of the Companies Act, 2013.
f	Indicative time period for completion of the acquisition	The Proposed Transaction is expected to be completed during the current financial year, subject to the completion of customary closing conditions and agreements which includes transfer of business of the Firm.
g	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash consideration
h	Cost of acquisition and/or the price at which the shares are acquired	The Proposed Transaction is contemplated by way of primary subscription to 10,833 equity shares of the SI&C at a consideration of Rs. 32.50 Crores, equivalent to 52% of the post-issue paid-up equity capital of SI&C.
i	Percentage of shareholding / control acquired and / or number of shares acquired	The Company will hold 52% shareholding on closing of the Proposed Transaction through primary subscription to equity share capital. Post the Proposed Transaction, the SI&C will be a subsidiary company of the Company.
j	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<u>Brief background and line of business:</u> SI&C specializes in the manufacturing and supply of high-quality polymer and silica-based products for the chemical, pharmaceutical, and biotechnology industries. Wide range of products for various applications are as hereunder: ○ Peptide and Peptidomimetic Synthesis; ○ Absorption and separation of the heavy metals; ○ Oxidation and reduction of the functional groups; ○ Counter – Ion exchange of small molecules and APIs <u>Date of incorporation:</u> SI&C is incorporated on July 15, 2026. SI&C will take over the business of a partnership firm, namely, M/s SI & C Resins (the “Firm”), wherein all the founder directors and shareholders of SI&C, are partners in the Firm. <u>Turnover of last 3 years:</u> Not applicable <u>Country in which the entity has presence:</u> SI&C has operation in India.

Registered Office

Laurus Labs Limited

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, **F** +91 891 682 1103

E info@lauruslabs.com, **W** lauruslabs.com

Corporate Office

Plot No. 103, Road No 1, Jubilee Hills,
Hyderabad, Telangana - 500 033, India.

T +91 40 6659 4333

F +91 40 6659 4320

CIN : L24239AP2005PLC047518